Key points are not available for this paper at this time.
MARROW transplantation provides the opportunity for aggressive antileukemic therapy without regard to marrow toxicity.1 We have reported the application of this approach combined with intensive chemoradiotherapy in patients with several classes of leukemia; these patients had received the maximum benefit of combination chemotherapy and were considered to be in the end stages of the disease.2 Marrow donors were either identical twins or HLA-identical siblings. Six of 16 recipients of syngeneic marrow and 14 of 110 recipients of allogeneic marrow are still in remission after four to nine years.3 , 4 The allogeneic recipients included 54 patients with acute nonlymphoblastic leukemia, six of . . .
Thomas et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: